Nuvectis Pharma, Inc. (NVCT)
NASDAQ: NVCT · Real-Time Price · USD
8.96
-0.08 (-0.88%)
At close: Mar 6, 2026, 4:00 PM EST
8.92
-0.04 (-0.45%)
After-hours: Mar 6, 2026, 4:04 PM EST
Company Description
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology.
The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021.
Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Nuvectis Pharma, Inc.
| Country | United States |
| Founded | 2020 |
| IPO Date | Feb 4, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Ron Bentsur |
Contact Details
Address: 1 Bridge Plaza, 2nd Floor, Suite 275 Fort Lee, New Jersey 07024 United States | |
| Phone | 201 614 3150 |
| Website | nuvectis.com |
Stock Details
| Ticker Symbol | NVCT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001875558 |
| CUSIP Number | 67080T108 |
| ISIN Number | US67080T1088 |
| Employer ID | 86-2405608 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ron Bentsur M.B.A. | Co-Founder, Chairman, Chief Executive Officer and President |
| Dr. Enrique Poradosu Ph.D. | Co-Founder, Executive Vice President, Chief Scientific and Business Officer |
| Shay Shemesh | Co-Founder, Executive Vice President, Chief Development and Operations Officer |
| Michael Carson CPA | Vice President of Finance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 20, 2026 | EFFECT | Notice of Effectiveness |
| Feb 13, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Feb 11, 2026 | 8-K | Current Report |
| Feb 11, 2026 | 10-K | Annual Report |
| Nov 4, 2025 | 8-K | Current Report |
| Nov 4, 2025 | 10-Q | Quarterly Report |
| Sep 25, 2025 | 8-K | Current Report |
| Aug 5, 2025 | 10-Q | Quarterly Report |
| Aug 5, 2025 | 8-K | Current Report |
| Jun 13, 2025 | 8-K | Current Report |